Drug repositioning: Playing dirty to kill pain

CNS Drugs

Volumn 28, Issue 1, 2014, Pages 45-61

  Bastos, Leandro Francisco Silva ^a   Coelho, Márcio Matos ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Faculdade de Farmacia   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANALGESIC AGENT; ANESTHETIC AGENT; ANTIASTHMATIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA LACTAM ANTIBIOTIC; BUPIVACAINE; CARBAMAZEPINE; CEFTRIAXONE; CELECOXIB; DOXYCYCLINE; FENOTEROL; IBUDILAST; KETAMINE; LIDOCAINE; MINOCYCLINE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; ORCIPRENALINE; OXCARBAZEPINE; RALFINAMIDE; RAPAMYCIN; RIFAMPICIN; SALBUTAMOL; TAPENTADOL; TERBUTALINE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG;

ALLODYNIA; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CANCER PAIN; COST EFFECTIVENESS ANALYSIS; DIABETIC NEUROPATHY; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG REPOSITIONING; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; GLOSSOPHARYNGEAL NEURALGIA; HEADACHE; HUMAN; HYPERALGESIA; LOW BACK PAIN; MIGRAINE; NEURALGIA; NEUROPATHIC PAIN; NONHUMAN; PAIN; PERIPHERAL NERVE INJURY; PHANTOM PAIN; POLYNEUROPATHY; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TRIGEMINUS NEURALGIA;

ANALGESICS; ANIMALS; DRUG DESIGN; DRUG INDUSTRY; DRUG REPOSITIONING; HUMANS; MOLECULAR TARGETED THERAPY; PAIN; RESEARCH; WORLD HEALTH;

EID: 84893518899     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0128-0     Document Type: Review

References (178)

1. Raju TN. The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98). Lancet. 2000;355(9208):1022.
2. Mullard A. 2011 FDA drug approvals. Nat Rev Drug Discov. 2012;11(2):91-4.
3. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673-83.
4. Innovation or stagnation: challenge and opportunity on the critical path to new medical products. U.S. Department of Health and Human Services, The U.S. Food and Drug Administration; 2004. p. 38.
5. Cavalla D. Therapeutic switching: a new strategic approach to enhance R&D productivity. IDrugs. 2005;8(11):914-8.
6. Reaume AG. Drug repurposing through nonhypothesis driven phenotypic screening. Drug Discov Today Ther Strateg. 2012;8(3-4):85-8.
7. Tobinick EL. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect. 2009;22(2):119-25.
8. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):711-5.
9. Melnikova I. Pain market. Nat Rev Drug Discov. 2010;9(8):589-90.
10. Nightingale S. The neuropathic pain market. Nat Rev Drug Discov. 2012;11(2):101-2.
11. Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136(3):380-7.
12. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin: results from a general population survey. J Pain. 2006;7(4):281-9.
13. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-53.
14. Kotz J. Phenotypic screening, take two. SciBX: Science-Business Exchange; 2012. p. 1-3.
15. Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;10(7):507-19.
16. Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006;5(10):821-34.
17. Zambrowicz BP, Sands AT. Knockouts model the 100 best-selling drugs - will they model the next 100? Nat Rev Drug Discov. 2003;2(1):38-51.
18. Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2006;444(7121):894-8.
19. Nassar MA, Levato A, Stirling LC, Wood JN. Neuropathic pain develops normally in mice lacking both Na(v)1.7 and Na(v)1.8. Mol Pain. 2005;1:24.
20. Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375(9722):1255-66.
21. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380(9851):1387-95.
22. Frantz S. Drug discovery: playing dirty. Nature. 2005;437(7061):942-3.
23. Mogil JS, Davis KD, Derbyshire SW. The necessity of animal models in pain research. Pain. 2010;151(1):12-7.
24. Rice AS, Cimino-Brown D, Eisenach JC, Kontinen VK, Lacroix-Fralish ML, Machin I, et al. Animal models and the prediction of efficacy in clinical trials of analgesic drugs: a critical appraisal and call for uniform reporting standards. Pain. 2008;139(2):243-7.
25. McCarberg BH, Billington R. Consequences of neuropathic pain: quality-of-life issues and associated costs. Am J Manag Care. 2006;12(9 Suppl):S263-8.
26. Cobos EJ, Ghasemlou N, Araldi D, Segal D, Duong K, Woolf CJ. Inflammation-induced decrease in voluntary wheel running in mice: a nonreflexive test for evaluating inflammatory pain and analgesia. Pain. 2012;153(4):876-84.
27. Langford DJ, Bailey AL, Chanda ML, Clarke SE, Drummond TE, Echols S, et al. Coding of facial expressions of pain in the laboratory mouse. Nat Methods. 2010;7(6):447-9.
28. King T, Vera-Portocarrero L, Gutierrez T, Vanderah TW, Dussor G, Lai J, et al. Unmasking the tonic-aversive state in neuropathic pain. Nat Neurosci. 2009;12(11):1364-6.
29. Mogil JS. Sex differences in pain and pain inhibition: multiple explanations of a controversial phenomenon. Nat Rev Neurosci. 2012;13(12):859-66.
30. Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley JL 3rd. Sex, gender, and pain: a review of recent clinical and experimental findings. J Pain. 2009;10(5):447-85.
31. Mogil JS. Animal models of pain: progress and challenges. Nat Rev Neurosci. 2009;10(4):283-94.
32. Greenspan JD, Craft RM, LeResche L, Arendt-Nielsen L, Berkley KJ, Fillingim RB, et al. Studying sex and gender differences in pain and analgesia: a consensus report. Pain. 2007;132(Suppl 1):S26-45.
33. Rezende RM, Paiva-Lima P, Dos Reis WG, Camelo VM, Bakhle YS, de Francischi JN. Celecoxib induces tolerance in a model of peripheral inflammatory pain in rats. Neuropharmacology. 2010;59(6):551-7.
34. Challapalli V, Tremont-Lukats IW, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev. 2005(4):CD003345.
35. Tremont-Lukats IW, Challapalli V, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis. Anesth Analg. 2005;101(6):1738-49.
36. Chong C, Schug SA, Page-Sharp M, Jenkins B, Ilett KF. Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: preliminary findings from a three-way randomized, crossover study. Clin Drug Investig. 2009;29(5):317-24.
37. Alviar MJ, Hale T, Dungca M. Pharmacologic interventions for treating phantom limb pain. Cochrane Database Syst Rev. 2011(12):CD006380.
38. Chaparro LE, Smith SA, Moore RA, Wiffen PJ, Gilron I. Pharmacotherapy for the prevention of chronic pain after surgery in adults. Cochrane Database Syst Rev. 2013;7:CD008307.
39. Dahmani S, Michelet D, Abback PS, Wood C, Brasher C, Nivoche Y, et al. Ketamine for perioperative pain management in children: a meta-analysis of published studies. Paediatr Anaesth. 2011;21(6):636-52.
40. Zhou HY, Chen SR, Pan HL. Targeting N-methyl-d-aspartate receptors for treatment of neuropathic pain. Expert Rev Clin Pharmacol. 2011;4(3):379-88.
41. Christensen K, Rogers E, Green GA, Hamilton DA, Mermelstein F, Liao E, et al. Safety and efficacy of intranasal ketamine for acute postoperative pain. Acute Pain. 2007;9(4):183-92.
42. Carr DB, Goudas LC, Denman WT, Brookoff D, Staats PS, Brennen L, et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain. 2004;108(1-2):17-27.
43. Suzumura A, Ito A, Yoshikawa M, Sawada M. Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res. 1999;837(1-2):203-12.
44. Mizuno T, Kurotani T, Komatsu Y, Kawanokuchi J, Kato H, Mitsuma N, et al. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology. 2004;46(3):404-11.
45. Ledeboer A, Liu T, Shumilla JA, Mahoney JH, Vijay S, Gross MI, et al. The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol. 2006;2(4):279-91.
46. Hama AT, Broadhead A, Lorrain DS, Sagen J. The antinociceptive effect of the asthma drug ibudilast in rat models of peripheral and central neuropathic pain. J Neurotrauma. 2012;29(3):600-10.
47. Hutchinson MR, Lewis SS, Coats BD, Skyba DA, Crysdale NY, Berkelhammer DL, et al. Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast). Brain Behav Immun. 2009;23(2):240-50.
48. Lilius TO, Rauhala PV, Kambur O, Kalso EA. Modulation of morphine-induced antinociception in acute and chronic opioid treatment by ibudilast. Anesthesiology. 2009;111(6):1356-64.
49. Rolan P, Hutchinson M, Johnson K. Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease. Expert Opin Pharmacother. 2009;10(17):2897-904.
50. Choucair-Jaafar N, Yalcin I, Rodeau JL, Waltisperger E, Freund-Mercier MJ, Barrot M. Beta2-adrenoceptor agonists alleviate neuropathic allodynia in mice after chronic treatment. Br J Pharmacol. 2009;158(7):1683-94.
51. Yalcin I, Tessier LH, Petit-Demouliere N, Waltisperger E, Hein L, Freund-Mercier MJ, et al. Chronic treatment with agonists of beta(2)-adrenergic receptors in neuropathic pain. Exp Neurol. 2010;221(1):115-21.
52. Cok OY, Eker HE, Yalcin I, Barrot M, Aribogan A. Is there a place for beta-mimetics in clinical management of neuropathic pain? Salbutamol therapy in six cases. Anesthesiology. 2010;112(5):1276-9.
53. WHO Model List of Essential Medicines. 18th ed. Geneva, Switzerland: World Health Organization; 2013. p. 41.
54. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433(7021):73-7.
55. Chandrasekar PH, Rolston KV, Smith BR, LeFrock JL. Diffusion of ceftriaxone into the cerebrospinal fluid of adults. J Antimicrob Chemother. 1984;14(4):427-30.
56. Lin Y, Tian G, Roman K, Handy C, Travers JB, Lin CL, et al. Increased glial glutamate transporter EAAT2 expression reduces visceral nociceptive response in mice. Am J Physiol Gastrointest Liver Physiol. 2009;296(1):G129-34.
57. Lin Y, Roman K, Foust KD, Kaspar BK, Bailey MT, Stephens RL. Glutamate transporter GLT-1 upregulation attenuates visceral nociception and hyperalgesia via spinal mechanisms not related to anti-inflammatory or probiotic effects. Pain Res Treat. 2011;2011:507029.
58. Hu Y, Li W, Lu L, Cai J, Xian X, Zhang M, et al. An anti-nociceptive role for ceftriaxone in chronic neuropathic pain in rats. Pain. 2010;148(2):284-301.
59. Ramos KM, Lewis MT, Morgan KN, Crysdale NY, Kroll JL, Taylor FR, et al. Spinal upregulation of glutamate transporter GLT-1 by ceftriaxone: therapeutic efficacy in a range of experimental nervous system disorders. Neuroscience. 2010;169(4):1888-900.
60. Chen Z, He Y, Wang ZJ. The beta-lactam antibiotic, ceftriaxone, inhibits the development of opioid-induced hyperalgesia in mice. Neurosci Lett. 2012;509(2):69-71.
61. Bastos LFS, de Oliveira ACP, Watkins LR, Moraes MFD, Coelho MM. Tetracyclines and pain. Naunyn Schmiedebergs Arch Pharmacol. 2012;385(3):225-41.
62. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA. 1998;95(26):15769-74.
63. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA. 1999;96(23):13496-500.
64. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci. 2009;10(1):23-36.
65. Raghavendra V, Tanga F, DeLeo JA. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther. 2003;306(2):624-30.
66. Ledeboer A, Sloane EM, Milligan ED, Frank MG, Mahony JH, Maier SF, et al. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain. 2005;115(1-2):71-83.
67. Bastos LFS, Merlo LA, Rocha LTS, Coelho MM. Characterization of the antinociceptive and anti-inflammatory activities of doxycycline and minocycline in different experimental models. Eur J Pharmacol. 2007;576(1-3):171-9.
68. Nakamae T, Ochi M, Olmarker K. Pharmacological inhibition of tumor necrosis factor may reduce pain behavior changes induced by experimental disc puncture in the rat: an experimental study in rats. Spine. 2011;36(4):E232-6.
69. Mika J, Wawrzczak-Bargiela A, Osikowicz M, Makuch W, Przewlocka B. Attenuation of morphine tolerance by minocycline and pentoxifylline in naive and neuropathic mice. Brain Behav Immun. 2009;23(1):75-84.
70. Bastos LF, Prazeres JD, Godin AM, Menezes RR, Soares DG, Ferreira WC, et al. Sex-independent suppression of experimental inflammatory pain by minocycline in two mouse strains. Neurosci Lett. 2013;11(553):110-4.
71. Aronson AL. Pharmacotherapeutics of the Newer Tetracyclines. J Am Vet Med Assoc. 1980;176(10):1061-8.
72. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci USA. 1996;93(24):14014-9.
73. 2 in BV2 microglial cells. Arch Pharm Res. 2004;27(3):314-8.
74. Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci USA. 2006;103(25):9685-90.
75. Nikodemova M, Duncan ID, Watters JJ. Minocycline exerts inhibitory effects on multiple mitogen-activated protein kinases and IkappaBalpha degradation in a stimulus-specific manner in microglia. J Neurochem. 2006;96(2):314-23.
76. Nikodemova M, Watters JJ, Jackson SJ, Yang SK, Duncan ID. Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII. J Biol Chem. 2007;282(20):15208-16.
77. Mika J, Rojewska E, Makuch W, Przewlocka B. Minocycline reduces the injury-induced expression of prodynorphin and pronociceptin in the dorsal root ganglion in a rat model of neuropathic pain. Neuroscience. 2010;165(4):1420-8.
78. Bastos LFS, de Oliveira ACP, Schlachetzki JCM, Fiebich BL. Minocycline reduces prostaglandin E synthase expression and 8-isoprostane formation in LPS-activated primary rat microglia. Immunopharm Immunotoxicol. 2011;33(3):576-80.
79. Bastos LFS, Godin AM, Zhang Y, Jarussophon S, Ferreira BC, Machado RR, et al. A minocycline derivative reduces nerve injury-induced allodynia, LPS-induced prostaglandin E2 microglial production and signaling via Toll-like receptors 2 and 4. Neurosci Lett. 2013;24(543):157-62.
80. Patel RN, Attur MG, Dave MN, Patel IV, Stuchin SA, Abramson SB, et al. A novel mechanism of action of chemically modified tetracyclines: inhibition of COX-2-mediated prostaglandin E2 production. J Immunol. 1999;163(6):3459-67.
81. Bastos LFS, Angusti A, Vilaca MC, Merlo LA, Nascimento EB, Rocha LTS, et al. A novel non-antibacterial, non-chelating hydroxypyrazoline derivative of minocycline inhibits nociception and oedema in mice. Br J Pharmacol. 2008;155(5):714-21.
82. Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol. 1996;134(4):693-5.
83. Martinez V, Szekely B, Lemarie J, Martin F, Gentili M, Ben Ammar S, et al. The efficacy of a glial inhibitor, minocycline, for preventing persistent pain after lumbar discectomy: a randomized, double-blind, controlled study. Pain. 2013;154:1197-203.
84. da Costa BR, Nuesch E, Reichenbach S, Juni P, Rutjes AW. Doxycycline for osteoarthritis of the knee or hip. Cochrane Database Syst Rev. 2012;11:CD007323.
85. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-39.
86. Wang X, Grace PM, Pham MN, Cheng K, Strand KA, Smith C, et al. Rifampin inhibits Toll-like receptor 4 signaling by targeting myeloid differentiation protein 2 and attenuates neuropathic pain. FASEB J. 2013;27(7):2713-22.
87. Caruso I, Montrone F, Fumagalli M, Patrono C, Santandrea S, Gandini MC. Rheumatoid knee synovitis successfully treated with intra-articular rifamycin SV. Ann Rheum Dis. 1982;41(3):232-6.
88. Waszkielewicz AM, Gunia A, Sloczynska K, Marona H. Evaluation of anticonvulsants for possible use in neuropathic pain. Curr Med Chem. 2011;18(28):4344-58.
89. McNamara JO. Pharmacotherapy of the epilepsies. In: Brunton LL, Chabner B, Knollman BC, Goodman LS, editors. Goodman & Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; 2011. p. 583-607.
90. Hearn L, Derry S, Moore RA. Lacosamide for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012;2:CD009318.
91. Wiffen PJ, Derry S, Moore RA. Lamotrigine for acute and chronic pain. Cochrane Database Syst Rev. 2011(2):CD006044.
92. Wiffen PJ, Derry S, Lunn MP, Moore RA. Topiramate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2013;8:CD008314.
93. O'Donnell JM, Shelton RC. Drug therapy of depression and anxiety disorders. In: Brunton LL, Chabner B, Knollman BrC, Goodman LS, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 2011. p. 397-416.
94. Kadiroglu AK, Sit D, Kayabasi H, Tuzcu AK, Tasdemir N, Yilmaz ME. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. J Diabetes Complications. 2008;22(4):241-5.
95. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004;110(3):697-706.
96. Smitherman TA, Walters AB, Maizels M, Penzien DB. The use of antidepressants for headache prophylaxis. CNS Neurosci Ther. 2011;17(5):462-9.
97. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012;12:CD008242.
98. Richards BL, Whittle SL, Buchbinder R. Antidepressants for pain management in rheumatoid arthritis. Cochrane Database Syst Rev. 2011(11):CD008920.
99. Hauser W, Wolfe F, Tolle T, Uceyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs. 2012;26(4):297-307.
100. Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet. 2009;374(9697):1252-61.
101. Oliveira AC, Bertollo CM, Rocha LT, Nascimento EB Jr, Costa KA, Coelho MM. Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma. Eur J Pharmacol. 2007;561(1-3):194-201.
102. Churi SB, Abdel-Aleem OS, Tumber KK, Scuderi-Porter H, Taylor BK. Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats. J Pain. 2008;9(7):639-49.
103. Jia H, Zhu S, Ji Q, Hui K, Duan M, Xu J, et al. Repeated administration of pioglitazone attenuates development of hyperalgesia in a rat model of neuropathic pain. Exp Clin Psychopharmacol. 2010;18(4):359-65.
104. Takahashi Y, Hasegawa-Moriyama M, Sakurai T, Inada E. The macrophage-mediated effects of the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone attenuate tactile allodynia in the early phase of neuropathic pain development. Anesth Analg. 2011;113(2):398-404.
105. Morgenweck J, Abdel-Aleem OS, McNamara KC, Donahue RR, Badr MZ, Taylor BK. Activation of peroxisome proliferator-activated receptor gamma in brain inhibits inflammatory pain, dorsal horn expression of Fos, and local edema. Neuropharmacology. 2010;58(2):337-45.
106. Watkins LR, Hutchinson MR, Rice KC, Maier SF. The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci. 2009;30(11):581-91.
107. Hutchinson MR, Zhang Y, Brown K, Coats BD, Shridhar M, Sholar PW, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of Toll-like receptor 4 (TLR4). Eur J Neurosci. 2008;28(1):20-9.
108. Hutchinson MR, Northcutt AL, Hiranita T, Wang X, Lewis SS, Thomas J, et al. Opioid activation of Toll-like receptor 4 contributes to drug reinforcement. J Neurosci. 2012;32(33):11187-200.
109. Lewis SS, Loram LC, Hutchinson MR, Li CM, Zhang Y, Maier SF, et al. (+)-naloxone, an opioid-inactive Toll-like receptor 4 signaling inhibitor, reverses multiple models of chronic neuropathic pain in rats. J Pain. 2012;13(5):498-506.
110. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663-72.
111. Shin EJ, Nah SY, Chae JS, Bing G, Shin SW, Yen TP, et al. Dextromethorphan attenuates trimethyltin-induced neurotoxicity via sigma1 receptor activation in rats. Neurochem Int. 2007;50(6):791-9.
112. Shin EJ, Nah SY, Kim WK, Ko KH, Jhoo WK, Lim YK, et al. The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan. Br J Pharmacol. 2005;144(7):908-18.
113. Gambito ED, Gonzalez-Suarez CB, Oquinena TI, Agbayani RB. Evidence on the effectiveness of topical nitroglycerin in the treatment of tendinopathies: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2010;91(8):1291-305.
114. McCleane G. The analgesic efficacy of topical capsaicin is enhanced by glyceryl trinitrate in painful osteoarthritis: a randomized, double blind, placebo controlled study. Eur J Pain. 2000;4(4):355-60.
115. McCleane GJ, McLaughlin M. The addition of GTN to capsaicin cream reduces the discomfort associated with application of capsaicin alone. A volunteer study. Pain. 1998;78(2):149-51.
116. Walsh KE, Berman JR, Berman LA, Vierregger K. Safety and efficacy of topical nitroglycerin for treatment of vulvar pain in women with vulvodynia: a pilot study. J Gend Specif Med. 2002;5(4):21-7.
117. Fletcher S, Wright M, Wilkinson A, Farr M, Sellars L. Locally applied transdermal nitrate patches for the treatment of ischaemic rest pain. Int J Clin Pract. 1997;51(5):324-5.
118. Dutra MM, Godin AM, Cesar IC, Nascimento EB Jr, Menezes RR, Ferreira WC, et al. Activity of nicorandil, a nicotinamide derivative with a nitrate group, in the experimental model of pain induced by formaldehyde in mice. Pharmacol Biochem Behav. 2013;106C:85-90.
119. Datta S, Waghray T, Torres M, Glusman S. Amiodarone decreases heat, cold, and mechanical hyperalgesia in a rat model of neuropathic pain. Anesth Analg. 2004;98(1):178-84.
120. Akada Y, Ogawa S, Amano K, Fukudome Y, Yamasaki F, Itoh M, et al. Potent analgesic effects of a putative sodium channel blocker M58373 on formalin-induced and neuropathic pain in rats. Eur J Pharmacol. 2006;536(3):248-55.
121. McGowan E, Hoyt SB, Li X, Lyons KA, Abbadie C. A peripherally acting Na(v)1.7 sodium channel blocker reverses hyperalgesia and allodynia on rat models of inflammatory and neuropathic pain. Anesth Analg. 2009;109(3):951-8.
122. Carroll IR, Kaplan KM, Mackey SC. Mexiletine therapy for chronic pain: survival analysis identifies factors predicting clinical success. J Pain Symptom Manage. 2008;35(3):321-6.
123. Giovannoni MP, Ghelardini C, Vergelli C, Dal Piaz V. Alpha2-agonists as analgesic agents. Med Res Rev. 2009;29(2):339-68.
124. Blaudszun G, Lysakowski C, Elia N, Tramer MR. Effect of perioperative systemic alpha2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials. Anesthesiology. 2012;116(6):1312-22.
125. Engelman E, Marsala C. Efficacy of adding clonidine to intrathecal morphine in acute postoperative pain: meta-analysis. Br J Anaesth. 2013;110(1):21-7.
126. Schnabel A, Reichl SU, Poepping DM, Kranke P, Pogatzki-Zahn EM, Zahn PK. Efficacy and safety of intraoperative dexmedetomidine for acute postoperative pain in children: a meta-analysis of randomized controlled trials. Paediatr Anaesth. 2013;23(2):170-9.
127. Nakamura M, Ferreira SH. A peripheral sympathetic component in inflammatory hyperalgesia. Eur J Pharmacol. 1987;135(2):145-53.
128. Davidson EM, Doursout MF, Szmuk P, Chelly JE. Antinociceptive and cardiovascular properties of esmolol following formalin injection in rats. Can J Anaesth. 2001;48(1):59-64.
129. Favaro-Moreira NC, Parada CA, Tambeli CH. Blockade of beta(1)-, beta(2)- and beta(3)-adrenoceptors in the temporomandibular joint induces antinociception especially in female rats. Eur J Pain. 2012;16(9):1302-10.
130. Chen YW, Chu CC, Chen YC, Hung CH, Wang JJ. Propranolol elicits cutaneous analgesia against skin nociceptive stimuli in rats. Neurosci Lett. 2012;524(2):129-32.
131. Dorazil-Dudzik M, Mika J, Schafer MK, Li Y, Obara I, Wordliczek J, et al. The effects of local pentoxifylline and propentofylline treatment on formalin-induced pain and tumor necrosis factor-alpha messenger RNA levels in the inflamed tissue of the rat paw. Anesth Analg. 2004;98(6):1566-73.
132. Vale ML, Benevides VM, Sachs D, Brito GA, da Rocha FA, Poole S, et al. Antihyperalgesic effect of pentoxifylline on experimental inflammatory pain. Br J Pharmacol. 2004;143(7):833-44.
133. Liu J, Feng X, Yu M, Xie W, Zhao X, Li W, et al. Pentoxifylline attenuates the development of hyperalgesia in a rat model of neuropathic pain. Neurosci Lett. 2007;412(3):268-72.
134. Liu J, Li W, Zhu J, Zhang J, Feng X, Guan R, et al. The effect of pentoxifylline on existing hypersensitivity in a rat model of neuropathy. Anesth Analg. 2008;106(2):650-3.
135. Mika J. Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness. Pharmacol Rep. 2008;60(3):297-307.
136. Izadpanah F, Mojtahedzadeh M. Kazem Aghamir SM, Atharikia D, Dashti S, Abbasi A. Effect of intravenous pentoxifylline in inflammatory response in patients undergoing nephrolithotomy. J Endourol. 2009;23(2):323-8.
137. Asomoza-Espinosa R, Alonso-Lopez R, Mixcoatl-Zecuatl T, Aguirre-Banuelos P, Torres-Lopez JE, Granados-Soto V. Sildenafil increases diclofenac antinociception in the formalin test. Eur J Pharmacol. 2001;418(3):195-200.
138. Mixcoatl-Zecuatl T, Aguirre-Banuelos P, Granados-Soto V. Sildenafil produces antinociception and increases morphine antinociception in the formalin test. Eur J Pharmacol. 2000;400(1):81-7.
139. Ambriz-Tututi M, Velazquez-Zamora DA, Urquiza-Marin H, Granados-Soto V. Analysis of the mechanism underlying the peripheral antinociceptive action of sildenafil in the formalin test. Eur J Pharmacol. 2005;512(2-3):121-7.
140. Lee HG, Kim WM, Choi JI, Yoon MH. Roles of adenosine receptor subtypes on the antinociceptive effect of sildenafil in rat spinal cord. Neurosci Lett. 2010;480(3):182-5.
141. Rocha FA, Silva FS Jr, Leite AC, Leite AK, Girao VC, Castro RR, et al. Tadalafil analgesia in experimental arthritis involves suppression of intra-articular TNF release. Br J Pharmacol. 2011;164(2b):828-35.
142. Araiza-Saldana CI, Rocha-Gonzalez HI, Ambriz-Tututi M, Castaneda-Corral G, Caram-Salas NL, Hong E, et al. Sildenafil and glyceryl trinitrate reduce tactile allodynia in streptozotocin-injected rats. Eur J Pharmacol. 2010;631(1-3):17-23.
143. Wang L, Chopp M, Szalad A, Liu Z, Bolz M, Alvarez FM, et al. Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice. Neuroscience. 2011;13(193):399-410.
144. Bender G, Florian JA Jr, Bramwell S, Field MJ, Tan KK, Marshall S, et al. Pharmacokinetic-pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain. J Pharmacol Exp Ther. 2010;334(2):599-608.
145. Groeneweg G, Huygen FJ, Niehof SP, Wesseldijk F, Bussmann JB, Schasfoort FC, et al. Effect of tadalafil on blood flow, pain, and function in chronic cold complex regional pain syndrome: a randomized controlled trial. BMC Musculoskelet Disord. 2008;9:143.
146. Grace PM, Rolan PE, Hutchinson MR. Peripheral immune contributions to the maintenance of central glial activation underlying neuropathic pain. Brain Behav Immun. 2011;25(7):1322-32.
147. Geranton SM, Jimenez-Diaz L, Torsney C, Tochiki KK, Stuart SA, Leith JL, et al. A rapamycin-sensitive signaling pathway is essential for the full expression of persistent pain states. J Neurosci. 2009;29(47):15017-27.
148. Price TJ, Rashid MH, Millecamps M, Sanoja R, Entrena JM, Cervero F. Decreased nociceptive sensitization in mice lacking the fragile X mental retardation protein: role of mGluR1/5 and mTOR. J Neurosci. 2007;27(51):13958- 67.
149. Xu Q, Fitzsimmons B, Steinauer J, O'Neill A, Newton AC, Hua XY, et al. Spinal phosphinositide 3-kinase-Akt-mammalian target of rapamycin signaling cascades in inflammation-induced hyperalgesia. J Neurosci. 2011;31(6):2113-24.
150. Norsted Gregory E, Codeluppi S, Gregory JA, Steinauer J, Svensson CI. Mammalian target of rapamycin in spinal cord neurons mediates hypersensitivity induced by peripheral inflammation. Neuroscience. 2010;169(3):1392-402.
151. Asante CO, Wallace VC, Dickenson AH. Mammalian target of rapamycin signaling in the spinal cord is required for neuronal plasticity and behavioral hypersensitivity associated with neuropathy in the rat. J Pain. 2010;11(12):1356-67.
152. Orhan CE, Onal A, Ulker S. Antihyperalgesic and antiallodynic effect of sirolimus in neuropathic pain and the role of cytokines in this effect. Neurosci Lett. 2010;481(1):17-20.
153. Orhan CE, Onal A, Uyanikgil Y, Ulker S. Antihyperalgesic and antiallodynic effect of sirolimus in rat model of adjuvant arthritis. Eur J Pharmacol. 2013;705(1-3):35-41.
154. Shih MH, Kao SC, Wang W, Yaster M, Tao YX. Spinal cord NMDA receptor-mediated activation of mammalian target of rapamycin is required for the development and maintenance of bone cancer-induced pain hypersensitivities in rats. J Pain. 2012;13(4):338-49.
155. George A, Marziniak M, Schafers M, Toyka KV, Sommer C. Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain. 2000;88(3):267-75.
156. Gu X, Zheng Y, Ren B, Zhang R, Mei F, Zhang J, et al. Intraperitoneal injection of thalidomide attenuates bone cancer pain and decreases spinal tumor necrosis factor-alpha expression in a mouse model. Mol Pain. 2010;6:64.
157. Ribeiro RA, Vale ML, Ferreira SH, Cunha FQ. Analgesic effect of thalidomide on inflammatory pain. Eur J Pharmacol. 2000;391(1-2):97-103.
158. Barsante MM, Roffe E, Yokoro CM, Tafuri WL, Souza DG, Pinho V, et al. Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. Eur J Pharmacol. 2005;516(3):282-9.
159. Wahane VD, Kumar VL. Atorvastatin ameliorates inflammatory hyperalgesia in rat model of monoarticular arthritis. Pharmacol Res. 2010;61(4):329-33.
160. Garcia GG, Miranda HF, Noriega V, Sierralta F, Olavarria L, Zepeda RJ, et al. Antinociception induced by atorvastatin in different pain models. Pharmacol Biochem Behav. 2011;100(1):125-9.
161. Miranda HF, Noriega V, Olavarria L, Zepeda RJ, Sierralta F, Prieto JC. Antinociception and anti-inflammation induced by simvastatin in algesiometric assays in mice. Basic Clin Pharmacol Toxicol. 2011;109(6):438-42.
162. Shi XQ, Lim TK, Lee S, Zhao YQ, Zhang J. Statins alleviate experimental nerve injury-induced neuropathic pain. Pain. 2011;152(5):1033-43.
163. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005;258(2):94-114.
164. Godin AM, Ferreira WC, Rocha LT, Ferreira RG, Paiva AL, Merlo LA, et al. Nicotinic acid induces antinociceptive and anti-inflammatory effects in different experimental models. Pharmacol Biochem Behav. 2012;101(3):493-8.
165. Lanska DJ. Chapter 30: historical aspects of the major neurological vitamin deficiency disorders: the water-soluble B vitamins. Handb Clin Neurol. 2010;95:445-76.
166. Stracke H, Lindemann A, Federlin K. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes. 1996;104(4):311-6.
167. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1346-53.
168. Franca DS, Souza AL, Almeida KR, Dolabella SS, Martinelli C, Coelho MM. B vitamins induce an antinociceptive effect in the acetic acid and formaldehyde models of nociception in mice. Eur J Pharmacol. 2001;421(3):157-64.
169. Godin AM, Ferreira WC, Rocha LT, Seniuk JG, Paiva AL, Merlo LA, et al. Antinociceptive and anti-inflammatory activities of nicotinamide and its isomers in different experimental models. Pharmacol Biochem Behav. 2011;99(4):782-8.
170. Cuzzocrea S, Zingarelli B, Caputi AP. Peroxynitrate-mediated DNA strand breakage activates poly(ADP-ribose) synthetase and causes cellular energy depletion in a nonseptic shock model induced by zymosan in the rat. Shock. 1998;9(5):336-40.
171. Wang ZB, Gan Q, Rupert RL, Zeng YM, Song XJ. Thiamine, pyridoxine, cyanocobalamin and their combination inhibit thermal, but not mechanical hyperalgesia in rats with primary sensory neuron injury. Pain. 2005;114(1-2):266-77.
172. Song XS, Huang ZJ, Song XJ. Thiamine suppresses thermal hyperalgesia, inhibits hyperexcitability, and lessens alterations of sodium currents in injured, dorsal root ganglion neurons in rats. Anesthesiology. 2009;110(2):387-400.
173. Jolivalt CG, Mizisin LM, Nelson A, Cunha JM, Ramos KM, Bonke D, et al. B vitamins alleviate indices of neuropathic pain in diabetic rats. Eur J Pharmacol. 2009;612(1-3):41-7.
174. Granados-Soto V, Teran-Rosales F, Rocha-Gonzalez HI, Reyes-Garcia G, Medina-Santillan R, Rodriguez-Silverio J, et al. Riboflavin reduces hyperalgesia and inflammation but not tactile allodynia in the rat. Eur J Pharmacol. 2004;492(1):35-40.
175. Bertollo CM, Oliveira AC, Rocha LT, Costa KA, Nascimento EB Jr, Coelho MM. Characterization of the antinociceptive and anti-inflammatory activities of riboflavin in different experimental models. Eur J Pharmacol. 2006;547(1-3):184-91.
176. Brand C, Snaddon J, Bailey M, Cicuttini F. Vitamin E is ineffective for symptomatic relief of knee osteoarthritis: a six month double blind, randomised, placebo controlled study. Ann Rheum Dis. 2001;60(10):946-9.
177. Edmonds SE, Winyard PG, Guo R, Kidd B, Merry P, Langrish-Smith A, et al. Putative analgesic activity of repeated oral doses of vitamin E in the treatment of rheumatoid arthritis. Results of a prospective placebo controlled double blind trial. Ann Rheum Dis. 1997;56(11):649-55.
178. Lu R, Kallenborn-Gerhardt W, Geisslinger G, Schmidtko A. Additive antinociceptive effects of a combination of vitamin C and vitamin E after peripheral nerve injury. PLoS ONE. 2011;6(12):e29240.